secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2022-06-22T23:59:59+00:00
Accession:  0001851734-22-000341
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VistaGen terminates President/CSO; PH94B Phase 3 trial completes enrollment
---------------------------------------------------------------------------

- President and CSO H. Ralph Snodgrass terminated effective June 15, 2022.
- Last patient completed protocol in PALISADE-1 Phase 3 trial of PH94B for social anxiety disorder.
- Topline results from PALISADE-1 expected mid-2022; PALISADE-2 topline expected late-2022.
- FDA granted Fast Track designation for PH94B in social anxiety disorder.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000185173422000341/0001851734-22-000341-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000185173422000341/vtgn20220622_8k.htm
  HTML page:      https://secwatch.observer/filing/0001851734-22-000341

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer